Cellectis (CLLS) Tops Q2 EPS by 25c

Cellectis (NASDAQ: CLLS) reported Q2 EPS of ($0.19), $0.25 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $2 million versus the consensus estimate of $4.48 million.

For earnings history and earnings-related data on Cellectis (CLLS) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• Lamb Weston (LW) Tops Q4 EPS by 25c; offers guidance
• TPU-As-A-Service could boost Google’s 2028 profit by over 15%: Barclays